Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lederle

Executive Summary

Launching Zosyn combination I.V. antibiotic with an average wholesale price of $95.75 for a 2.25 gram single-dose vial; $144 for 3.375 g; and $192 for 4.5 g. The "usual total daily dose" is 3.375 g every six hours ("The Pink Sheet" Nov. 1, T&G-4). Lederle and MedImmune sign definitive cross-marketing agreement to copromote Zosyn and MedImmune's RespiGam (formerly Respivir), the firms announce Nov. 9. The agreement also covers codevelopment and promotion of two other potential respiratory syncytial virus products: a MAb from MedImmune and a Lederle vaccine ("The Pink Sheet" July 19, T&G-11).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel